


Project: Pluripotent Stem Cell-Derived Human Islet Organoids for Cure of Diabetes

PI: Prof. Zhou Zhongjun

Technology:



Description: Nordia Biotech, a start-up biotech company, utilizes the groundbreaking innovative technology developed by team in HKUMed, to treat diabetes by islet organoids production & transplantation into patients for long-term control of blood glucose levels through regeneration of islets to achieve steady insulin secretion.

Key Advantages:

- 模拟原生组织** Spontaneous 3D structure formation with full intercellular communications.
- 方法简单经济** Simple & cost effective by minimizing manual operation.
- 成分安全已知** Chemically-defined Ingredients enable clinical-grade production.
- 经验资本赋能** Rich experiences in research, management & financing: 20+ years in Academia & Industry; 7M HKD Series Angel; Pre-A round 1 is completion.
- 市场潜力巨大** Huge Market: 2+ Billion patients, \$240+ Billion Global Market in 2030
- 技术新兴领先** Leading Tech: Emerging advanced therapeutics
- 产品安全长效** Quality Products: No Immune Rejection + Long-term Effect.

Opportunities:

US Provisional patent 63/637,745, filed; Pre-A round 2 is on going...
PCT patent PCT/CN2025/090611 is under review

Contact:

✉ zhongjun@hku.hk
🌐 <https://www.sbms.hku.hk/staff/zhongjun-zhou>



Stage of Development:

Pre-IND Animal Experiments now; Clinical trails in two years